Addressing the Growing Colorectal Cancer Incidence in Younger Populations

Commentary
Video

Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.

Due to the “terrifying” rising incidence of colorectal cancer (CRC) in younger populations, it has become critical to perform screening more frequently among individuals even in their late 20s and 30s who might be at risk of developing this disease, suggested Gregory Charak, MD.

Charak, a board-certified colorectal surgeon at Palisades Medical Center and Hackensack University Medical Center of Hackensack Meridian Health, spoke with CancerNetwork® about his strategies for mitigating the rise in CRC cases among younger patients through increased screening procedures. In the event of weight changes, for instance, Charak said he and his colleagues would not hesitate to perform a colonoscopy to monitor younger at-risk individuals.

According to a news release from The American College of Surgeons, the rate of colon cancer diagnoses has increased by 15% since 2004 in patients ages 18 to 50 years old based on data derived from the National Cancer Database. Compared with this younger population, the rate of colon cancer diagnoses has increased by 3% among adults 45 to 55 years old across the same period. Factors such as environmental changes, exposure to toxins, and individual genetics are believed to have influenced this growth in diagnoses among younger populations.

Transcript:

It’s terrifying, and we don’t know what’s going on. Institutionally, or nationally, we’ve certainly taken this step of lowering the age of first screening for colorectal cancer. Now, we advise people with average risk at their first colonoscopy at 45. Personally, and certainly among my colleagues, we are much quicker to perform a colonoscopy and to go looking for something in our younger patients. If you are in your 30s, even in your late 20s, and you’re having changes in your weight or have blood in your stool, we won’t hesitate to perform a colonoscopy because we know that there’s a small possibility—but a real possibility—that there could be a cancer, and so we look.

Reference

Colorectal cancer awareness month: what to know about the rise of colorectal cancer in younger adults. News release. The American College of Surgeons. March 5, 2024. Accessed April 22, 2024. https://tinyurl.com/3ux2hnds

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Related Content